Marker Therapeutics (MRKR) Notes Payables (2010 - 2022)

Marker Therapeutics (MRKR) has reported Notes Payables for 11 consecutive years, with $2.5 million the latest figure, recorded in Q4 2022.

• On a quarterly basis, Notes Payables changed N/A year-over-year to $2.5 million in Q4 2022; TTM through Dec 2022 was $2.5 million, a N/A change from a year earlier, with the FY2022 full-year figure at $2.5 million, changed N/A from the prior year.
• Notes Payables was $2.5 million for Q4 2022 at Marker Therapeutics, down from $5.0 million in the prior quarter.
• Over five years, Notes Payables peaked at $8.0 million in Q2 2022 and troughed at $8000.0 in Q1 2018.
• A 3-year average of $1.5 million and a median of $107000.0 in 2018 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables surged 1683.33% in 2018 and sank 55.78% in 2019, its largest moves.
• Over 3 years, Notes Payables stood at $49000.0 in 2018, then slumped by 36.73% to $31000.0 in 2019, then jumped by 7964.52% to $2.5 million in 2022.
• The last three Notes Payables figures came in at $2.5 million (Q4 2022), $5.0 million (Q3 2022), and $8.0 million (Q2 2022), per Business Quant data.